[go: up one dir, main page]

DE1206274T1 - Verwendung von interleukin-18-inhibitoren zur hemmung von tumormetastasierung - Google Patents

Verwendung von interleukin-18-inhibitoren zur hemmung von tumormetastasierung

Info

Publication number
DE1206274T1
DE1206274T1 DE1206274T DE00944201T DE1206274T1 DE 1206274 T1 DE1206274 T1 DE 1206274T1 DE 1206274 T DE1206274 T DE 1206274T DE 00944201 T DE00944201 T DE 00944201T DE 1206274 T1 DE1206274 T1 DE 1206274T1
Authority
DE
Germany
Prior art keywords
inhibitor
receptor
inhibitors
derivative
mutein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DE1206274T
Other languages
English (en)
Inventor
Charles Dinarello
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Original Assignee
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research and Development Co Ltd filed Critical Yeda Research and Development Co Ltd
Publication of DE1206274T1 publication Critical patent/DE1206274T1/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Claims (9)

Europäische Patentanmeldung Nr. 00 944 201.3 Anmelder: Yeda Research and Development Co. Ltd. 27118PEP-WO/WWDA Ansprüche
1. Verwendung von Inhibitoren der IL-18 Produktion und/oder Wirkung bei der Herstellung von Medikamenten zur Inhibierung von Tumormetastasierung.
2. Verwendung nach Anspruch 1, wobei der Inhibitor der IL-18 Produktion ein Caspase-1 Inhibitor ist.
3. Verwendung nach Anspruch 1, wobei der Inhibitor der IL-18 Wirkung ausgewählt ist aus Antikörpern gegen IL-18, Antikörpern gegen eine der IL-18 Rezeptoruntereinheiten, Inhibitoren des Signalweges des IL-18 Rezeptors, Antagonisten von IL-18, die mit IL-18 kompetieren und den IL-18 Rezeptor blockieren und IL-18 Bindungsproteine, einem Mutein, einem Fusionsprotein, einem funktioneilen Derivat, einer aktiven Fraktion oder einem zirkulär permutiertes Derivat davon mit der gleichen Aktivität.
4. Verwendung nach Anspruch 3, wobei der Inhibitor der IL-18 Wirkung ein Antikörper gegen IL-18 ist.
5. Verwendung nach Anspruch 3, wobei der Inhibitor der IL-18 Wirkung ein IL-18 BP, oder ein Mutein, ein Derivat oder Fragment davon mit gleicher Aktivität wie IL-18 BP, ist.
6. Pharmazeutische Zusammensetzung zur Inhibierung der IL-18 Produktion und/oder Wirkung, um Tumormetastasierung zu inhibieren, umfassend Antikörper gegen IL-18, Antikörper gegen eine der IL-18
DE/EP 1 206274T1
Rezeptoruntereinheiten, Inhibitoren des Signalweges des IL-18 Rezeptors, Antagonisten von IL-18, die mit IL-18 kompetieren und den IL-18 Rezeptor blockieren und IL-18 Bindungsproteine, einem Mutein, ein Derivat oder Fragment davon mit gleicher Wirkung, das IL-18 bindet und seine biologische Aktivität blockiert.
7. Pharmazeutische Zusammensetzung nach Anspruch 6, umfassend einen Antikörper gegen IL-18.
8. Pharmazeutische Zusammensetzung nach Anspruch 6, umfassend ein IL-18 bindendes Protein, ein Mutein, ein Derivat oder Fragment davon mit der gleichen Aktivität.
9. Verwendung eines Expressionsvektors bei der Herstellung von Medikamenten zur Inhibierung von Tumormetastasierung, der für einen Inhibitor der IL-18 Produktion und/oder Wirkung kodiert.
DE1206274T 1999-07-22 2000-07-17 Verwendung von interleukin-18-inhibitoren zur hemmung von tumormetastasierung Pending DE1206274T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL13104799A IL131047A0 (en) 1999-07-22 1999-07-22 Use of il-18 inhibitors
PCT/IL2000/000419 WO2001007480A2 (en) 1999-07-22 2000-07-17 Use of interleukin-18 inhibitors to inhibit tumor metastasis

Publications (1)

Publication Number Publication Date
DE1206274T1 true DE1206274T1 (de) 2002-11-14

Family

ID=11073044

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60035049T Expired - Lifetime DE60035049T2 (de) 1999-07-22 2000-07-17 Verwendung von interleukin-18-inhibitoren zur hemmung von tumormetastasierung
DE1206274T Pending DE1206274T1 (de) 1999-07-22 2000-07-17 Verwendung von interleukin-18-inhibitoren zur hemmung von tumormetastasierung

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE60035049T Expired - Lifetime DE60035049T2 (de) 1999-07-22 2000-07-17 Verwendung von interleukin-18-inhibitoren zur hemmung von tumormetastasierung

Country Status (31)

Country Link
US (1) US7741276B2 (de)
EP (1) EP1206274B1 (de)
JP (1) JP4827352B2 (de)
KR (1) KR100682219B1 (de)
CN (1) CN1173736C (de)
AR (1) AR024907A1 (de)
AT (1) ATE363288T1 (de)
AU (1) AU782478B2 (de)
BG (1) BG65800B1 (de)
BR (1) BR0012675A (de)
CA (1) CA2380216C (de)
CY (1) CY1107932T1 (de)
CZ (1) CZ302114B6 (de)
DE (2) DE60035049T2 (de)
DK (1) DK1206274T3 (de)
EA (1) EA005419B1 (de)
EE (1) EE04838B1 (de)
ES (1) ES2186596T3 (de)
HK (1) HK1048248B (de)
HU (1) HU228780B1 (de)
IL (2) IL131047A0 (de)
MX (1) MXPA02000838A (de)
NO (1) NO329827B1 (de)
NZ (1) NZ516535A (de)
PL (1) PL202477B1 (de)
PT (1) PT1206274E (de)
SK (1) SK287522B6 (de)
TR (1) TR200200169T2 (de)
UA (1) UA73745C2 (de)
WO (1) WO2001007480A2 (de)
ZA (1) ZA200200390B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK12942002A3 (sk) * 2000-02-10 2003-05-02 Abbott Laboratories Protilátky viažuce ľudský interleukín-18, spôsoby ich výroby a použitia
AU2002211744B8 (en) 2000-10-11 2008-03-20 Viron Therapeutics, Inc. Nucleic acid molecules and polypeptides for immune modulation
US7718368B2 (en) 2000-12-04 2010-05-18 Viron Therapeutics Inc. Immunomodulatory protein and useful embodiments thereof
AU2003299919B2 (en) * 2002-10-08 2009-08-06 Ares Trading S.A. The use of cytokine able to bind IL-18BP and of inhibiting the activity of a second cytokine
US7968684B2 (en) * 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
ES2370417T3 (es) 2005-06-03 2011-12-15 Ares Trading S.A. Producción de una proteína de unión a il-18 recombinante.
PL1891088T3 (pl) 2005-06-10 2012-03-30 Ares Trading Sa Sposób oczyszczania białka wiążącego IL-18
CL2008002153A1 (es) 2007-07-24 2009-06-05 Amgen Inc Anticuerpo aislado o fragmanto de unión de antigeno del mismo que se une al receptor de il-18 (il-18r); molecula de ácido nucleico codificante; celula huesped que la comprende; composición farmaceutica; uso médico para tratar o prevenir una condición asociada con il-18r; método in vitro para inhibir la unión de il-18 al il-18r.
US9812033B2 (en) * 2013-03-06 2017-11-07 Venkatesh R. Chari Tactile graphic display
AU2023236289A1 (en) 2022-03-15 2024-08-15 Compugen Ltd. Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer
WO2025003753A1 (en) 2023-06-26 2025-01-02 Compugen Ltd. Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ256171A (en) * 1992-09-02 1996-12-20 Isis Pharmaceuticals Inc Treating diseases amenable to treatment through modulating intercellular adhesion molecule metabolism or synthesis using oligonucleotides
US7141393B2 (en) * 1996-12-26 2006-11-28 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18-receptor proteins
CN1269722A (zh) * 1997-03-18 2000-10-11 Basf公司 调节对皮质类固醇反应的方法及组合物
IL121860A0 (en) * 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use

Also Published As

Publication number Publication date
DK1206274T3 (da) 2007-08-13
ATE363288T1 (de) 2007-06-15
CA2380216C (en) 2012-01-31
BR0012675A (pt) 2002-04-09
JP4827352B2 (ja) 2011-11-30
BG65800B1 (bg) 2009-12-31
BRPI0012675B1 (pt) 2001-02-01
EE04838B1 (et) 2007-06-15
HU228780B1 (en) 2013-05-28
EE200200032A (et) 2003-02-17
NO20020153D0 (no) 2002-01-11
CZ2002195A3 (cs) 2002-06-12
CN1173736C (zh) 2004-11-03
WO2001007480A2 (en) 2001-02-01
NZ516535A (en) 2004-04-30
HUP0202107A3 (en) 2005-01-28
ES2186596T1 (es) 2003-05-16
NO329827B1 (no) 2011-01-03
CY1107932T1 (el) 2013-09-04
HUP0202107A2 (en) 2002-10-28
HK1048248A1 (en) 2003-03-28
BG106311A (en) 2002-08-30
NO20020153L (no) 2002-03-11
PL202477B1 (pl) 2009-06-30
EA200200189A1 (ru) 2002-12-26
US20080003216A1 (en) 2008-01-03
UA73745C2 (en) 2005-09-15
KR20020027493A (ko) 2002-04-13
AR024907A1 (es) 2002-10-30
DE60035049T2 (de) 2007-09-27
ZA200200390B (en) 2003-04-30
US7741276B2 (en) 2010-06-22
HK1048248B (zh) 2005-04-22
JP2003505472A (ja) 2003-02-12
AU5843200A (en) 2001-02-13
CZ302114B6 (cs) 2010-10-20
CA2380216A1 (en) 2001-02-01
BRPI0012675B8 (de) 2021-05-25
IL131047A0 (en) 2001-01-28
EA005419B1 (ru) 2005-02-24
MXPA02000838A (es) 2002-07-30
SK882002A3 (en) 2002-07-02
AU782478B2 (en) 2005-08-04
EP1206274A2 (de) 2002-05-22
WO2001007480A3 (en) 2001-05-10
EP1206274B1 (de) 2007-05-30
ES2186596T3 (es) 2007-11-16
TR200200169T2 (tr) 2002-06-21
CN1364086A (zh) 2002-08-14
PL353732A1 (en) 2003-12-01
DE60035049D1 (de) 2007-07-12
PT1206274E (pt) 2007-07-06
SK287522B6 (sk) 2011-01-04
KR100682219B1 (ko) 2007-02-12
IL147675A (en) 2009-05-04

Similar Documents

Publication Publication Date Title
DE1206274T1 (de) Verwendung von interleukin-18-inhibitoren zur hemmung von tumormetastasierung
DE102004014983A1 (de) Rekombinante Polypeptide der Mitglieder der TNF Ligandenfamilie und deren Verwendung
EP2062917A3 (de) Antikörper für einen Erythropoetin-Rezeptor und Verwendungen damit
EP1764370A3 (de) Methoden zur Behandlung von Entzündungskrankheiten unter Verwendung von Agentien welche spezifisch an menschliches Angiopoietin-2 binden
TWI347313B (en) Novel substituted phenoxyacetic acids,pharmaceutical composition comprising them,and use thereof
BR9813658A (pt) Cristais de peptìdeo-1 semelhantes a glucagÈnio
HUP0203836A3 (en) 1,3-disubstituted pyrrololidines as alpha-2-adrenoceptor antagonists, process for their preparation and pharmaceutical compositions containing them and their use
ATE176330T1 (de) Statistisch zufällige, pluripotente bio- oligomerenbank, eine methode solche zu synthetisieren und eine methode diese zu benützen
WO2005103102A3 (fr) Copolymere sequence
CA2010321A1 (en) Lymphocyte-associated cell surface protein
IL156262A0 (en) Anti-cd28 antibodies having no mitogenic activity and pharmaceutical compositions containing the same
RU2001132140A (ru) Рекомбинантный рецептор коллагена на тромбоцитах гликопротеин VI и его применение в фармацевтике
DE69720241D1 (de) Ligand (tie ligand-4) vom tie-2 rezeptor und dessen verwendungen
WO2001083693A8 (en) Compounds having affinity for the vascular endothelial growth factor receptor-2 (vegfr-2) and associated uses
WO2004081229A3 (en) Use of bv8 and/or eg-vegf to promote hematopoiesis
WO2004046096A3 (en) Novel ligands that are antagonists of raf receptors, process for preparing them and use thereof in human medicine and in cosmetics
NO20026286D0 (no) Nye peptider
DE69626387D1 (de) Antagonisten von humanem interleukin-6, welche zur bindung mit gp 130 unfähig sind und ihre verwendung in der herstellung von pharmazeutische zusammensetzungen
NO974057D0 (no) Bisykliske takykinin-antagonister, fremstilling derav og deres anvendelse i farmasöytisk sammensetning
CA2505506A1 (en) Compounds which can be used to diagnose and monitor diseases associated with the formation of amyloid protein fibrils
WO2004041296A3 (en) Pharmaceutical composition comprising a tissue factor antagonist and protein c polypeptides
ATE342977T1 (de) Nukleinsäure, die für polypeptide kodieren die eine mutt-domäne enthalten
DE60119347D1 (de) Verwendung von chimäres il6-il6r in huntingtonskrankheit
WO2002070563A3 (en) Nuclear hormone receptor ligand binding domain
DK0811068T3 (da) Humane DNase I varianter